Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Orion Market Research | PRODUCT CODE: 1159241

Cover Image

PUBLISHER: Orion Market Research | PRODUCT CODE: 1159241

Heterozygous Familial Hypercholesterolemia Drugs Market 2022-2028

PUBLISHED:
PAGES: 125 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4000
Printable PDF & Excel (Corporate License)
USD 6625

Add to Cart

Global Heterozygous Familial Hypercholesterolemia Drugs Market Size, Share & Trends Analysis Report By Type (Gemcabene Calcium, MGL-3196, ST- 103 and Others), And By Application (Hospital, Medical Center, Clinics and Others) Forecast 2022-2028

The global heterozygous familial hypercholesterolemia drug market is anticipated to grow at a CAGR during the forecast period. In the year 2020, heterozygous familial hypercholesterolemia affects 30 million people worldwide. This disease is mainly observed by high levels of low-density lipoprotein cholesterol. This condition usually arises right from birth. Major cases of heterozygous familial hypercholesterolemia occur due to variants in the gene which encode LDL receptors. A high level of LDL cholesterol increases the risk of atherosclerotic cardiovascular disease. LDL cholesterol levels can be reduced by consistent use of PCSK9 synthesis. For instance, in Feb 2020, Michigan-based Esperion's drug got approval from FDA which can be used as a non-statin cholesterol-lowering medication. The drug is named Nexlitol. This drug is at par in treatment as other drugs in cholesterol-lowering such as PCSK9.

The global heterozygous familial hypercholesterolemia drug market is segmented based on type and application. Based on type, the market is segmented into Gemcabene Calcium, MGL-3196, ST- 103, and Others. Based on application the market is sub-segmented into hospitals, Medical Center, Clinics, and Others. Among these, the hospital segment is anticipated to grow at a widespread rate during the forecast period. Diagnosis of such disease requires examination of blood, liver, kidney, and other variables. Health experts make sure that body variables are on a normal level to prescribe medications and further diagnosis. Body checkups are done in the hospital facility and prescription is done on that basis. For instance, in May 2021, Verve Therapeutics announced that it had worked upon gene editing medicines, and it will bring the publication of proof of data concept highlighting it which is for the treatment of cardiovascular disease. This is published in the Journal Nature. This study discusses the lowering of low-density lipoprotein cholesterol.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific is going to be a good market for heterozygous familial hypercholesterolemia drugs. In the past few years, the trend of the high cholesterol issue has been shifted to the Asia region from western countries as the consumption of beef and red meat has increased in these regions. Genetics are also responsible for increasing cholesterol problems in these regions. For instance, in June 2020, as per an article published in the journal Nature, examination of blood for 102.6 million people from all over the world. It was found that level of cholesterol was high in people of the middle-income group in Asia as compared to the high-income group in western countries.

The major companies serving the global heterozygous familial hypercholesterolemia drug market include Daewoong Corp.Ltd., Esperion Therapeutics, Inc., Gemphire Therapeutics, Inc., Madrigal Pharmaceuticals Inc., AbbVie Inc., and others. For instance, in April 2021, Praluent (alirocumab) was approved by FDA for lowering cholesterol levels in patients who have familial hypercholesterolemia.

Research Methodology

The market study of the global Heterozygous familial hypercholesterolemia drug market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Heterozygous familial hypercholesterolemia drugs market Research and Analysis by type.

2. Global Heterozygous familial hypercholesterolemia drugs market Research and Analysis by Application.

The Report Covers:

  • Comprehensive Research Methodology of the global Heterozygous familial hypercholesterolemia drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global Heterozygous familial hypercholesterolemia drug market.
  • Insights about market determinants that are stimulating the global Heterozygous familial hypercholesterolemia drug market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Product Code: OMR2026346

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on The Global Heterozygous familial hypercholesterolemia drugs Market
  • Recovery Scenario of Global Heterozygous familial hypercholesterolemia drugs Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Daewoong Corp.Ltd.
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Esperion Therapeutics Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Gemphire Therapeutics Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Madrigal Pharmaceuticals Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Abbvie Inc.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis
  • 3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global Heterozygous Familial Hypercholesterolemia Drugs Market By Type
    • 4.1.1. Gemcabene calcium
    • 4.1.2. MGL-3196
    • 4.1.3. ST-103
    • 4.1.4. Others
  • 4.2. Global Heterozygous Familial Hypercholesterolemia Drugs Market By End-User
    • 4.2.1. Hospital
    • 4.2.2. Medical center
    • 4.2.3. Clinics
    • 4.2.4. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Aegerion Pharmaceuticals Inc.
  • 6.2. Amgen Inc.
  • 6.3. AstraZeneca Plc
  • 6.4. Daiichi Sankyo Company Ltd.
  • 6.5. Esperion Therapeutics, Inc.
  • 6.6. Merck & Co., Inc
  • 6.7. Novartis AG
  • 6.8. Pfizer Inc.
  • 6.9. Sanofi S.A.
Product Code: OMR2026346

LIST OF TABLES

  • 1. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL GEMCABENE CALCIUM HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL MGL-3196 HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL ST-103 HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL OTHER HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUGS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 7. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG IN HOSPITAL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG IN MEDICAL CENTER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG IN CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 11. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG IN OTHER END-USER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 12. NORTH AMERICAN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 13. NORTH AMERICAN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 14. NORTH AMERICAN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 15. EUROPEAN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 16. EUROPEAN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 17. EUROPEAN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 18. ASIA-PACIFIC HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 19. ASIA-PACIFIC HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS TYPE, 2021-2028 ($ MILLION)
  • 20. ASIA-PACIFIC HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. REST OF THE WORLD HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 23. REST OF THE WORLD HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET, 2021-2027 (%)
  • 4. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL GEMCABENE CALCIUM HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL MGL-3196 HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL ST-103HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL OTHER HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUGs MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SHARE BY END-USER, 2021 VS 2028 (%)
  • 10. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG IN HOSPITAL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG IN MEDICAL CENTER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG IN CLINIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG IN OTHER END-USERS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 14. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. US HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. CANADA HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. UK HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. FRANCE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. GERMANY HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. ITALY HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. SPAIN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. REST OF EUROPE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. INDIA HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. CHINA HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. JAPAN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. SOUTH KOREA HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. REST OF THE WORLD HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!